Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128

Sort by

Sort Order Select

Journal Articles

The Genomic Landscape of Wilms' Tumor 1 ( WT1 ) Mutant Acute Myeloid Leukemia

Hassan Awada, MD, Arda Durmaz, Carmelo Gurnari, MD, Misam Zawit, MBBS, Sunisa Kongkiatkamon, MD, Simona Pagliuca, MD, Cassandra M. Kerr, MS, Hetty E. Carraway, MD MBA, Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139920

Published: 2020

Journal Articles

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Eric Parsons, RN, Jenna Thomas, Hetty E. Carraway, MD MBA, Dale Grabowski, BS, Yihong Guan, PhD, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Anjali S Advani, MD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139494

Published: 2020

Journal Articles

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

Yihong Guan, PhD, Metis Hasipek, PhD, Bhumika J. Patel, MD, Dale Grabowski, BS, Anand D. Tiwari, PhD, Sunisa Kongkiatkamon, MD, Cassandra M Kerr, MS, Aziz Nazha, MD, Yogenthiran Saunthararajah, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142875

Published: 2020

Journal Articles

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Andrea Massimiliano Tomirotti, PhD, Daniela Bellarosa, Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A Strickland, MD MSCI, Roland P Walter, MDPhD, Farhad Ravandi, MBBS, Krzysztof Brzózka, PhD, Milena Mazan, PhD, Simone Baldini, MD, Massimiliano Salerno, Monica Binaschi, PhD, Dirk Laurent, MD, Andrea Pellacani, PhD MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136936

Published: 2020

Journal Articles

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Aziz Nazha, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S Advani, MD, Madeline Waldron, PharmD, BCOP, Caitlin Siebenaller, PharmD, Jenna Thomas, Eric Parsons, RN, Hetty E. Carraway, MD MBA, Aaron T. Gerds, MDMS, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-139515

Published: 2020

Journal Articles

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Nathan Radakovich, BA, Luca Malcovati, MD, Manja Meggendorfer, PhD, Mikkael A. Sekeres, MD MS, Jacob Shreve, MD MS, Cameron Beau Hilton, MD, Yazan Rouphail, Wencke Walter, PhD, Stephan Hutter, PhD, Anna Gallì, Sarah Pozzi, Aaron T. Gerds, MDMS, Sudipto Mukherjee, MD PhD MPH, Cassandra M Kerr, MS, Babal K. Jha, PhD, Claudia Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Torsten Haferlach, MD, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-140023

Published: 2020

Journal Articles

Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

Yazan Rouphail, Nathan Radakovich, BA, Jacob Shreve, MD MS, Sudipto Mukherjee, MD PhD MPH, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-139522

Published: 2020

Journal Articles

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139013

Published: 2020

Journal Articles

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-139412

Published: 2020

Journal Articles

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Nathan Radakovich, BA, David A. Sallman, MD, Rena J. Buckstein, MD FRCPC, Andrew M. Brunner, MD, Sudipto Mukherjee, MD PhD MPH, Rami Komrokji, MD, Najla Al Ali, M.Sc, Jacob Shreve, MD MS, Yazan Rouphail, Cassandra M Kerr, MS, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-139815

Published: 2020

Journal Articles

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

Blood (2019) 134 (Supplement_1): 1270.

https://doi.org/10.1182/blood-2019-128967

Published: 2019

Journal Articles

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Yasunobu Nagata, MD PhD, Ran Zhao, Hassan Awada, Cassandra M Kerr, MS, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Jacob Scott, MD, Mikkael A. Sekeres, MD MS, Brian P. Hobbs, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1716.

https://doi.org/10.1182/blood-2019-127285

Published: 2019

Journal Articles

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 16.

https://doi.org/10.1182/blood-2019-130319

Published: 2019

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Blood (2019) 134 (Supplement_1): 2091.

https://doi.org/10.1182/blood-2019-128066

Published: 2019

Journal Articles

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Nathan Radakovich, BA, Mikkael A. Sekeres, MD MS, Cameron Beau Hilton, BA, Sudipto Mukherjee, MD PhD MPH, Jacob Shreve, MD MS, Yazan Rouphail, Rachel Shirley, Vera Adema, PhD, Hassan Awada, MD, Anjali S. Advani, MD, Cassandra M Kerr, MS, Yasunobu Nagata, MD PhD, Yihong Guan, PhD, Teodora Kuzmanovic, BA, Metis Hasipek, PhD, Babal K. Jha, PhD, Jaroslaw P. Maciejewski, MD PhD, Aziz Nazha, MD

Blood (2019) 134 (Supplement_1): 2089.

https://doi.org/10.1182/blood-2019-126275

Published: 2019

Journal Articles

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Caitlin Siebenaller, PharmD, Madeline Waldron, PharmD, BCOP, Kelly Gaffney, PharmD, Brian P. Hobbs, PhD, Ran Zhao, Marc Earl, PharmD, Marina Feldman, PharmD, BCCCP, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Bhumika J. Patel, MD, Betty K. Hamilton, MD, Ronald Sobecks, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2019) 134 (Supplement_1): 3433.

https://doi.org/10.1182/blood-2019-128807

Published: 2019

Journal Articles

Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors

Vera Adema, PhD, Courtney E Hershberger, BS, Wencke Walter, PhD, Cassandra M Kerr, MS, Stephan Hutter, PhD, Yasunobu Nagata, MD PhD, Hassan Awada, Sunisa Kongkiatkamon, Christina Snider, Milo Co, Manja Meggendorfer, PhD, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Francesc Sole, PhD, Richard A Padgett, PhD, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 2985.

https://doi.org/10.1182/blood-2019-129367

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia

Hassan Awada, Ashwin Kishtagari, MBBS, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Manja Meggendorfer, PhD, Anjali S. Advani, MD, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Torsten Haferlach, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2720.

https://doi.org/10.1182/blood-2019-131301

Published: 2019

Journal Articles

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Christina A. Snider, BA, Kevin Fung, Francesca Gould, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Hassan Awada, MD, Milo Co, Teodora Kuzmanovic, BA, Bhumika J. Patel, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 2696.

https://doi.org/10.1182/blood-2019-126311

Published: 2019

NARROW

The Genomic Landscape of Wilms' Tumor 1 ( WT1 ) Mutant Acute Myeloid Leukemia

A Phase I/II Trial of CPX-351 + Palbociclib in Patients with Acute Myeloid Leukemia

TET2 Inhibitory Effects of Eltrombopag Contribute Its Hematopoietic Activity

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure

Genotype-Phenotype Correlations in Patients with Myeloid Malignancies Using Explainable Artificial Intelligence

Personalized Transcriptomic Analyses Identify Unique Signatures That Correlate with Genomic Subtypes in Acute Myeloid Leukemia (AML) Using Explainable Artificial Intelligence

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

A Personalized Clinical-Decision Tool to Improve the Diagnostic Accuracy of Myelodysplastic Syndromes

Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)

Can Monosomy 7 be Targeted By Next Generation Cereblon-Modulating Agents?

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Predicting Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS) Using Artificial Intelligence (AI)

Identifying Factors That Predict for Unplanned Readmissions for Acute Myeloid Leukemia Patients Receiving Consolidation Cytarabine Based Therapies

Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Impact and Outcomes of RAS gene Mutations in Core Binding Factor Acute Myeloid Leukemia

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only